Property, Plant & Equipment
The latest quarterly pp&e is $830.40 Million with a quarter-over-quarter change of -3.80%. Property, Plant & Equipment (PP&E) represents the long-term tangible assets used in operations, including land, buildings, machinery, and equipment, shown net of accumulated depreciation.
PODD PP&E
Reported quarterly PP&E; no daily interpolation.
Current PP&E
$830.40M
$830.40 Million
Quarter-over-Quarter Change
-3.80%
vs. $863.20M prior quarter
Historical Data
80
Quarters of data available
Quarterly PP&E History
| Period | PP&E | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $830.40M | $-32.80M | -3.80% |
| Q4 2025 | $863.20M | +$139.10M | +19.21% |
| Q3 2025 | $724.10M | +$3.70M | +0.51% |
| Q2 2025 | $720.40M | +$1.70M | +0.24% |
| Q1 2025 | $718.70M | $-41.10M | -5.41% |
| Q4 2024 | $759.80M | +$56.90M | +8.10% |
| Q3 2024 | $702.90M | +$25.00M | +3.69% |
| Q2 2024 | $677.90M | +$10.20M | +1.53% |
| Q1 2024 | $667.70M | $-25.10M | -3.62% |
| Q4 2023 | $692.80M | +$43.60M | +6.72% |
| Q3 2023 | $649.20M | +$47.70M | +7.93% |
| Q2 2023 | $601.50M | +$4.90M | +0.82% |
| Q1 2023 | $596.60M | $-29.30M | -4.68% |
| Q4 2022 | $625.90M | +$72.80M | +13.16% |
| Q3 2022 | $553.10M | +$17.30M | +3.23% |
| Q2 2022 | $535.80M | $-2.40M | -0.45% |
| Q1 2022 | $538.20M | $-8.20M | -1.50% |
| Q4 2021 | $546.40M | +$31.00M | +6.01% |
| Q3 2021 | $515.40M | +$9.90M | +1.96% |
| Q2 2021 | $505.50M | +$7.60M | +1.53% |
| Q1 2021 | $497.90M | +$4.30M | +0.87% |
| Q4 2020 | $493.60M | +$44.40M | +9.88% |
| Q3 2020 | $449.20M | +$26.00M | +6.14% |
| Q2 2020 | $423.20M | +$10.80M | +2.62% |
| Q1 2020 | $412.40M | $-3.10M | -0.75% |
| Q4 2019 | $415.50M | +$47.45M | +12.89% |
| Q3 2019 | $368.06M | +$26.01M | +7.60% |
| Q2 2019 | $342.05M | +$34.15M | +11.09% |
| Q1 2019 | $307.89M | +$49.51M | +19.16% |
| Q4 2018 | $258.38M | +$28.95M | +12.62% |
| Q3 2018 | $229.43M | +$31.87M | +16.13% |
| Q2 2018 | $197.56M | +$44.53M | +29.10% |
| Q1 2018 | $153.03M | +$45.16M | +41.87% |
| Q4 2017 | $107.86M | +$19.37M | +21.89% |
| Q3 2017 | $88.49M | +$12.61M | +16.62% |
| Q2 2017 | $75.88M | +$10.60M | +16.24% |
| Q1 2017 | $65.28M | +$19.01M | +41.09% |
| Q4 2016 | $46.27M | $-4.64M | -9.12% |
| Q3 2016 | $50.91M | +$9.78M | +23.78% |
| Q2 2016 | $41.13M | $-564,000 | -1.35% |
| Q1 2016 | $41.70M | $-98,000 | -0.23% |
| Q4 2015 | $41.79M | +$257,000 | +0.62% |
| Q3 2015 | $41.54M | $-504,000 | -1.20% |
| Q2 2015 | $42.04M | $-2.57M | -5.77% |
| Q1 2015 | $44.61M | +$7.54M | +20.35% |
| Q4 2014 | $37.07M | +$487,000 | +1.33% |
| Q3 2014 | $36.58M | +$2.42M | +7.09% |
| Q2 2014 | $34.16M | +$1.60M | +4.92% |
| Q1 2014 | $32.56M | +$200,000 | +0.62% |
| Q4 2013 | $32.36M | +$957,000 | +3.05% |
| Q3 2013 | $31.40M | +$2.06M | +7.04% |
| Q2 2013 | $29.33M | +$4.35M | +17.42% |
| Q1 2013 | $24.98M | $-440,000 | -1.73% |
| Q4 2012 | $25.42M | +$512,000 | +2.06% |
| Q3 2012 | $24.91M | +$3.49M | +16.28% |
| Q2 2012 | $21.42M | +$1.48M | +7.39% |
| Q1 2012 | $19.95M | +$525,000 | +2.70% |
| Q4 2011 | $19.42M | +$1.13M | +6.16% |
| Q3 2011 | $18.30M | +$2.17M | +13.46% |
| Q2 2011 | $16.13M | +$1.87M | +13.11% |
| Q1 2011 | $14.26M | +$1.73M | +13.85% |
| Q4 2010 | $12.52M | $-1.63M | -11.49% |
| Q3 2010 | $14.15M | +$396,000 | +2.88% |
| Q2 2010 | $13.75M | $-1.38M | -9.14% |
| Q1 2010 | $15.13M | $-348,000 | -2.25% |
| Q4 2009 | $15.48M | $-49,000 | -0.32% |
| Q3 2009 | $15.53M | $-158,000 | -1.01% |
| Q2 2009 | $15.69M | $-734,000 | -4.47% |
| Q1 2009 | $16.42M | $-1.14M | -6.50% |
| Q4 2008 | $17.56M | $-8.52M | -32.65% |
| Q3 2008 | $26.08M | $-164,000 | -0.62% |
| Q2 2008 | $26.24M | +$1.02M | +4.04% |
| Q1 2008 | $25.23M | +$3.92M | +18.40% |
| Q4 2007 | $21.30M | +$344,000 | +1.64% |
| Q3 2007 | $20.96M | +$470,000 | +2.29% |
| Q2 2007 | $20.49M | +$2.01M | +10.85% |
| Q1 2007 | $18.48M | +$1.49M | +8.74% |
| Q4 2006 | $17.00M | +$1.32M | +8.40% |
| Q3 2006 | $15.68M | +$8.63M | +122.31% |
| Q4 2005 | $7.05M | — | — |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy